Pharmaceuticals

Oncology Clinical Trials Market Expected To Grow Steadily And Approach $5.99 Billion By 2030

May 1, 2026May 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Oncology Clinical Trials Market Between 2026 And 2030?

The oncology clinical trials market size has shown robust growth recently. It is projected to increase from $14.99 billion in 2025 to $15.98 billion in 2026, advancing at a compound annual growth rate (CAGR) of 6.6%. Historically, this expansion has been driven by factors such as limited treatment options for cancer patients, a rising global incidence of cancer, increased pharmaceutical and biotech R&D investments, the growing number of academic clinical research centers, and a heightened awareness regarding the importance of clinical trials.

The oncology clinical trials market size is anticipated to experience robust growth in the upcoming years. It is projected to expand to $20.4 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.3%. The market’s expansion during the forecast period can be attributed to the advancement of personalized oncology therapies, the broadening of multicenter and global trials, the implementation of digital patient monitoring tools, the incorporation of AI and big data in trial design, and increased governmental and private investment in oncology research. Significant trends for the forecast period include the growth of immunotherapy and targeted therapy clinical trials, an escalating emphasis on multicenter and randomized controlled trials, greater investment in post-marketing surveillance and long-term safety studies, the increasing embrace of cell and gene therapy trials, and the integration of biomarker and pharmacogenomics studies into oncology research.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27371&type=smp

Which Major Drivers Are Influencing The Expansion Of The Oncology Clinical Trials Market?

The rising occurrence of cancer is projected to stimulate the expansion of the oncology clinical trials market in the foreseeable future. Cancer incidence refers to the count of new cancer cases identified within a particular population over a defined timeframe. The surge in cancer incidence largely stems from unhealthy lifestyle choices, such as inadequate diet, lack of physical activity, tobacco consumption, and excessive alcohol intake, which heighten the likelihood of developing various cancers. Oncology clinical trials play a crucial role in enhancing cancer treatment by assessing novel therapies and interventions, thereby improving patient well-being through research supported by evidence. These trials expedite medical innovation through the evaluation of safety and efficacy, fostering advancements in cancer prevention, diagnosis, and care. For instance, in October 2025, the National Health Service (NHS), a UK-based government health agency, reported 354,820 new cancer diagnoses in 2023, averaging 972 daily, which represents an increase of 8,605 compared to 2022. Consequently, the escalating cancer incidence is propelling the growth of the oncology clinical trials.

Which Segment Categories Are Included In The Oncology Clinical Trials Market Segment Analysis?

The oncology clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Study Design: Interventional, Observational, Expanded Access

3) By Therapeutic Modality: Immunotherapy, Targeted Therapy, Chemotherapy, Cell And Gene Therapy, Other Therapeutic Modalities

4) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Blood Cancer, Other Indications

5) By Sponsor Type: Pharmaceutical And Biotech Companies, Academic And Research Institutes, Government Organizations, Other Sponsor Types

Subsegments:

1) By Phase I: Safety And Dosage Studies, Pharmacokinetics And Pharmacodynamics Studies, Biomarker Identification Studies

2) By Phase II: Efficacy And Side Effects Studies, Dose-Response Relationship Studies, Therapeutic Effectiveness Studies

3) By Phase III: Large-Scale Efficacy Studies, Comparative Effectiveness Studies, Multicenter Randomized Controlled Trials

4) By Phase IV: Post Marketing Surveillance Studies, Long-Term Safety Studies, Quality Of Life Studies

Which Trends Are Influencing Demand In The Oncology Clinical Trials Market?

Key companies operating in the oncology clinical trials market are prioritizing the development of technologically advanced solutions, such as sophisticated bioinformatics platforms, to improve data analysis, hasten patient recruitment, and enhance trial outcomes. Advanced bioinformatics platforms are complex software systems that employ computational tools and algorithms to collect, analyze, and interpret intricate biological and clinical data for research and healthcare applications. For instance, in September 2023, Deep 6 AI, a US-based healthcare technology company, launched an AI-powered genomics module aimed at accelerating enrollment in precision medicine and oncology clinical trials. This module utilizes artificial intelligence and natural language processing to extract both structured and unstructured genomics data from electronic medical records, enabling the real-time identification and accurate matching of patients with specific genetic markers. It provides researchers with the capacity to search millions of records for more than 19,000 genes and 30,000 mutation names, substantially speeding up patient recruitment and boosting the efficiency of clinical trial design.

Who Are The Active Companies Shaping The Oncology Clinical Trials Market?

Major companies operating in the oncology clinical trials market are Pfizer Inc., Johnson & Johnson, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Genentech Inc., BeiGene Ltd., Seagen Inc.

Get The Full Oncology Clinical Trials Market Report:

https://www.thebusinessresearchcompany.com/report/oncology-clinical-trials-global-market-report

Which Region Is The Top Contributor To The Oncology Clinical Trials Market By Share?

North America was the largest region in the oncology clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Oncology Clinical Trials Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/oncology-clinical-trials-global-market-report

Browse Through More Reports Similar to the Global Oncology Clinical Trials Market 2026, By The Business Research Company

Concrete Materials Market Report 2026

https://www.thebusinessresearchcompany.com/report/concrete-materials-global-market-report

Decorative Concrete Market Report 2026

https://www.thebusinessresearchcompany.com/report/decorative-concrete-global-market-report

Cellular Concrete Market Report 2026

https://www.thebusinessresearchcompany.com/report/cellular-concrete-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795